2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.35 Schneider

PP01.35 Schneider - Poster

Pdf Summary

The document provides an update on the TRIDENT-1 trial evaluating the efficacy and safety of repotrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Repotrectinib, a next-generation ROS1 and TRK tyrosine kinase inhibitor, demonstrated durable clinical activity in both treatment-naïve and pretreated patients with ROS1 advanced NSCLC. In the study, patients showed high response rates and prolonged progression-free survival, with manageable safety profiles. Notably, patients without baseline brain metastasis had significant intracranial responses. The drug also showed activity in patients with specific ROS1 mutations. Importantly, no on-target resistance mutations were observed in NAÔve patients who progressed on repotrectinib. The most common adverse event reported was dizziness, with most cases manageable and non-treatment-limiting. The continuation of durable clinical activity, prevention of brain lesions, and manageable safety profile suggest repotrectinib as a promising treatment option for ROS1 NSCLC patients. These findings support the potential for repotrectinib to become a new standard of care for both treatment-naïve and pretreated patients with ROS1 NSCLC. The results were presented at the IASLC Targeted Therapies of Lung Cancer Meeting and provide valuable insights into the efficacy and safety of repotrectinib in this patient population.

Keywords

TRIDENT-1 trial

repotrectinib

ROS1 fusion-positive

non-small cell lung cancer

NSCLC

tyrosine kinase inhibitor

progression-free survival

brain metastasis

ROS1 mutations

adverse events